Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
News May 19, 2015
Proteros biostructures GmbH has announced that it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV ("Janssen") triggering an undisclosed payment to Proteros.
Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic areas. The objective of this oncology focused project was for Proteros to discover potent and selective small molecule inhibitor series against a novel protein target.
Based on the establishment of a de novo X-ray crystallography system, HTS screening and biophysical assay technology of the novel target Proteros delivered multiple chemical series meeting stringent compound criteria.
Dr. Peter Reinemer, Chief Operating Officer for Proteros, stated: "We are very pleased to be Janssen's partner in one of their oncology discovery programs and that we have been able to deliver new compound classes for a challenging novel drug target."
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018